JP2024522620A - アトピー性皮膚炎及び関連する障害の治療方法 - Google Patents

アトピー性皮膚炎及び関連する障害の治療方法 Download PDF

Info

Publication number
JP2024522620A
JP2024522620A JP2023575802A JP2023575802A JP2024522620A JP 2024522620 A JP2024522620 A JP 2024522620A JP 2023575802 A JP2023575802 A JP 2023575802A JP 2023575802 A JP2023575802 A JP 2023575802A JP 2024522620 A JP2024522620 A JP 2024522620A
Authority
JP
Japan
Prior art keywords
binding protein
subject
use according
dose
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522620A5 (https=
Inventor
マーク，トーマス
ソルドブロー，リーセ
ビェアアゴー ウーラン，クリスチャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2024522620A publication Critical patent/JP2024522620A/ja
Publication of JP2024522620A5 publication Critical patent/JP2024522620A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023575802A 2021-06-11 2022-06-10 アトピー性皮膚炎及び関連する障害の治療方法 Pending JP2024522620A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108379.5A GB202108379D0 (en) 2021-06-11 2021-06-11 Methods for treating a topic dermatitis and related disorders
GB2108379.5 2021-06-11
PCT/EP2022/065851 WO2022258814A1 (en) 2021-06-11 2022-06-10 Methods for treating atopic dermatitis and related disorders

Publications (2)

Publication Number Publication Date
JP2024522620A true JP2024522620A (ja) 2024-06-21
JP2024522620A5 JP2024522620A5 (https=) 2025-06-17

Family

ID=76954592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575802A Pending JP2024522620A (ja) 2021-06-11 2022-06-10 アトピー性皮膚炎及び関連する障害の治療方法

Country Status (9)

Country Link
US (1) US20250059269A1 (https=)
EP (1) EP4351641A1 (https=)
JP (1) JP2024522620A (https=)
AU (1) AU2022289697A1 (https=)
CA (1) CA3221119A1 (https=)
GB (1) GB202108379D0 (https=)
IL (1) IL309053A (https=)
TW (1) TW202317184A (https=)
WO (1) WO2022258814A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026508149A (ja) * 2023-02-13 2026-03-10 インターベット インターナショナル ベー． フェー． イヌｉｌ－１３に対するイヌ抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
AU2006296399B2 (en) 2005-09-30 2011-01-20 Medimmune Limited Interleukin-13 antibody composition
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais

Also Published As

Publication number Publication date
IL309053A (en) 2024-02-01
TW202317184A (zh) 2023-05-01
CA3221119A1 (en) 2022-12-15
AU2022289697A1 (en) 2023-12-21
GB202108379D0 (en) 2021-07-28
EP4351641A1 (en) 2024-04-17
WO2022258814A1 (en) 2022-12-15
US20250059269A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
US11167004B2 (en) Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
KR102927870B1 (ko) Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
RU2759630C2 (ru) Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
WO2021195530A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
US20230167171A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
US12187788B2 (en) Methods for treating atopic dermatitis and related disorders
US20250059269A1 (en) Methods for treating atopic dermatitis and related disorders
EP4126943B1 (en) Methods for treating atopic dermatitis and related disorders
US20240400669A1 (en) Methods for treating atopic dermatitis and related disorders
RU2801204C2 (ru) Способ лечения атопического дерматита посредством введения ингибитора ил-4r
KR20210010518A (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250609